ClinicalTrials.gg

Program

EGFR Mutant-specific Inhibitor DZD6008

Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Dizal Pharmaceuticals.

Furthest: phase 2, since Jul 10, 20253 company-led studies, 3 open or runningNext primary completion: Sep 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Dizal Pharmaceuticals33 open or runningphase 2since Jul 10, 2025Dec 23, 2024Sep 2027phase 1 · NCT06905197

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 23, 2024First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT06813365 · 300 planned · China
  2. Mar 25, 2025Phase 1 study in Carcinoma, Non-Small-Cell LungNCT06905197 · 140 planned · United States, Australia
  3. Jul 10, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07079475 · 220 planned · China

Ahead

  1. Sep 2027Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT06905197
  2. Oct 30, 2027Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT06813365
  3. Jun 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07079475

TargetBeta

EGFR →read by rule
“An orally available, blood-brain-barrier (BBB) penetrant, mutant-specific inhibitor of the receptor tyrosine kinase epidermal growth factor receptor (EGFR), ”NCIt, by rule

Other programs on EGFR

ProgramCompanyFurthest phaseStudies
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 355
pimurutamabFosun Pharmaphase 317
Anti-EGFR Antibody-drug Conjugate CPO301CSPC Pharmaceutical Groupphase 316
sunvozertinibruleDizal Pharmaceuticalsphase 312
becotatugCSPC Pharmaceutical Groupphase 311
andamertinibruleavistone-biotechnology-co-ltdphase 310
becotatug vedotinrulelepu-biopharma-co-ltdphase 310
sevabertinibruleBayerphase 38
HS-10504Hansoh Pharmaceutical Groupphase 37
befotertinibruleBetta Pharmaceuticalsphase 36
petosemtamabruleGenmabphase 36
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07079475Carcinoma, Non-Small-Cell Lung · China2RecruitingJun 2028220
NCT06905197Carcinoma, Non-Small-Cell Lung · United States, Australia1RecruitingSep 2027140
NCT06813365Carcinoma, Non-Small-Cell Lung · China1RecruitingOct 30, 2027300

How it is read

Names in the registry

  • “DZD6008”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.